Skip to Content

Pindolol Pregnancy and Breastfeeding Warnings

Pindolol is also known as: Visken

Pindolol Pregnancy Warnings

Pindolol has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. There are no controlled data in human pregnancy. Pindolol should only be given during pregnancy when need has been clearly established.

Beta-blockers, including pindolol, are generally considered relatively safe during pregnancy. Pindolol crosses the human placenta. The average maternal serum to umbilical cord pindolol concentration ratio is 0.37 and 0.67 two and four hours after dosing, respectively. No reports of teratogenicity have been associated with pindolol, but there are limited data to show significantly decreased birth weight among the offspring whose mothers were treated with pindolol. In one (uncontrolled) study, over one third of the infants from hypertensive mothers who had received pindolol were of low birth weight. Because this study is uncontrolled, and the expected incidence of low birth weight babies exceeds one-third among women with hypertension, no clear cause-and-effect relationship between the use of pindolol and low birth weight can be made. While there are no reports of signs or symptoms of beta-blockade among infants whose mothers received pindolol, fetal and neonatal bradycardia and hypoglycemia have been associated with the use of other nonselective beta-blockers. Most experts recommend monitoring the neonate for signs and symptoms of beta-blockade during the first 48 hours postpartum.

See references

Pindolol Breastfeeding Warnings

Pindolol is excreted into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Grunstein S, Ellenbogen A, Anderman S, Davidson A, Jaschevatzky O "Transfer of pindolol across the placenta in hypertensive pregnant women." Curr Ther Res Clin Exp 37 (1985): 587-91
  2. Dubois D, Petitcolas J, Temperville B, Klepper A "Beta blockers and high-risk pregnancies." Int J Biol Res Pregnancy 1 (1980): 141-5
  3. Dubois D, Petitcolas J, Temperville B, Klepper A, Catherine P "Treatment of hypertension in pregnancy with B-adrenoceptor antagonists." Br J Clin Pharmacol 13 (1982): s375-8
  4. Hirsch M, Bar J, Bottkanner G, Kaplan B, Fuchs J, Ovadia J "Effect of the beta-adrenergic blocker pindolol on platelet function in chronic hypertensive pregnancy." Hypertens Pregnancy 15 (1996): 193-202
  5. Sukerman-Voldman E "Pindolol therapy in pregnant hypertensive patients." Br J Clin Pharmacol 13 (1982): s379
  6. Ingemarsson I, Liedholm H, Montan S, Westgren M, Melander A "Fetal heart rate during treatment of maternal hypertension with beta-adrenergic antagonists." Acta Obstet Gynecol Scand Suppl 118 (1984): 95-7
  7. "Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  8. Frishman WH, Chesner M "Beta-adrenergic blockers in pregnancy." Am Heart J 115 (1988): 147-52

References for breastfeeding information

  1. "Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.